Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.
Wedig J, Jasani S, Mukherjee D, Lathrop H, Matreja P, Pfau T, D'Alesio L, Guenther A, Fenn L, Kaiser M, Torok MA, McGue J, Sizemore GM, Noonan AM, Dillhoff ME, Blaser BW, Frankel TL, Culp S, Hart PA, Cruz-Monserrate Z, Mace TA. Wedig J, et al. Among authors: blaser bw. Cancer Immunol Immunother. 2024 Apr 15;73(6):96. doi: 10.1007/s00262-024-03678-6. Cancer Immunol Immunother. 2024. PMID: 38619621 Free PMC article.
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. Romagné F, et al. Among authors: blaser bw. Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24. Blood. 2009. PMID: 19553639 Free PMC article.
CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson WE 3rd, Mace TA. Choueiry F, et al. Among authors: blaser bw. J Immunother Cancer. 2020 Jun;8(1):e000189. doi: 10.1136/jitc-2019-000189. Epub 2020 Jun 23. J Immunother Cancer. 2020. PMID: 32581043 Free PMC article.
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE 3rd. Schwarz E, et al. Among authors: blaser bw. JCI Insight. 2024 Nov 8;9(21):e169927. doi: 10.1172/jci.insight.169927. JCI Insight. 2024. PMID: 39513363 Free PMC article. Clinical Trial.
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE 3rd. Savardekar H, et al. Among authors: blaser bw. Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572. Mol Cancer Res. 2024. PMID: 38015751 Free PMC article.
41 results